Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-29

Clinical Trial Update: Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing capecitabine with S-1 in unresectable or recurrent breast cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Capecitabine (capecitabine)
  • S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Japan Breast Cancer Research Network | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-05-29